Cupid promoter raises stake as Q1 profit jumps 194%; FY27 guidance increases

Chairman Aditya Kumar Halwasiya bought 13.96 lakh shares, taking his personal holding to 33.39%. Cupid reported Q1 FY27 revenue of Rs 156.98 crore, up 142% year-on-year, with EBITDA margin reaching 39%, and guided for FY27 revenue of Rs 725-750 crore.

— Source published Mon, 17 Aug, 2026, 17:51 IST · First seen Mon, 17 Aug, 2026, 18:25 IST · Source Business Today · Latest

What happened

Cupid Ltd · Cupid’s chairman Aditya Kumar Halwasiya raised his stake through an open-market purchase. The consumer healthcare and FMCG company reported sharp Q1

Key facts

  • Promoter Aditya Kumar Halwasiya bought 13,95,538 shares (0.10% equity)
  • Halwasiya personal stake: 33.39%
  • Promoter group stake: 46.34%
  • Q1 FY27 net profit: Rs 44.15 crore, up 194% YoY
  • Q1 FY27 total income: Rs 156.98 crore, up 142% YoY
  • Q1 FY27 EBITDA: Rs 60.06 crore, up 265% YoY
  • Q1 FY27 EBITDA margin: 39%, up 1,127 bps YoY
  • FY27 revenue guidance: Rs 725-750 crore
  • FY27 net profit guidance: Rs 210-225 crore
  • Share price closed at Rs 270.90, down 7.82%

Why this matters

Cupid’s rapidly expanding scale, high margins and visible promoter conviction could make it a more credible partner or acquisition candidate in consumer healthcare, though buyers should test the durability of its growth drivers.

What to watch

  • Q2 revenue growth versus the Q1 142% year-on-year pace and progress toward the Rs 725-750 crore FY27 target.
  • EBITDA margin durability near 39%, including gross-margin movement and selling-expense intensity.
  • Operating cash flow, receivable days, inventory build and need for incremental working-capital financing.
  • Disclosure of major customer, tender, export or distribution wins and the degree of customer concentration.
  • Further promoter purchases or pledging activity, along with institutional ownership changes.
  • Regulatory approvals, product launches, capacity additions and any quality or compliance observations.
  • Accelerate consumer-healthcare distribution expansion across pharmacy, modern trade, e-commerce and export channels.
  • Use promoter stake increase in investor communication to reinforce confidence in FY27 execution and capital discipline.
  • Prioritize inventory, receivables and production planning to prevent working-capital strain from rapid revenue scaling.
  • Sustain high-margin product mix through new launches, brand-building and cross-selling rather than relying solely on bulk or tender-led sales.
  • Expand manufacturing and quality-control capacity ahead of demand while maintaining regulatory compliance.